Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference

Via Peters

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company will deliver two podium presentations on 24-month data from the TOPAZ Phase 2 clinical trial at the 2022 SMA […]

Rock Steady Boxing

Via Peters

NEW BERN, N.C. — Parkinson’s disease is the fastest growing neurological disorder, according to a study. Ten million people worldwide are living with the disease. According to a 2018 study, that number is expected to grow by a couple million over the next 20 years. What You Need To Know […]